Key Takeaways
- Shares of NVO plummeted approximately 8% on Monday, marking the largest single-session decline since February
- CEO Mike Doustdar revealed the company is exploring mergers and acquisitions to address pipeline deficiencies, especially in cardiovascular therapeutics
- The company’s blockbuster drugs Ozempic and Wegovy, representing roughly 75% of revenue, will lose patent protection in the early 2030s
- Management aims to launch 5+ blockbuster products before 2030 and generate more than $23 billion in additional revenue by 2035
- Share repurchases totaling DKK 9.63 billion have been completed under the company’s DKK 15 billion buyback initiative
Novo Nordisk shares experienced a sharp decline of nearly 8% on Monday following a capital markets presentation that left investors unconvinced about the pharmaceutical giant’s future growth trajectory. The stock closed at $39.80, representing a $3.44 decline, with further weakness emerging in Tuesday’s trading session.
Market participants interpreted the company’s long-term projections as underwhelming, suggesting the targets were already incorporated into current valuations rather than offering upside potential.
CEO Mike Doustdar addressed the negative market response during an appearance on CNBC’s “Squawk Box Europe,” stating: “We talked about diversification of the company, but yet the reaction tells me that there’s still some work to do in convincing some of the investors.”
Doustdar further conceded that restoring investor confidence remains a priority. “What we have learned the last couple of years is overpromising and underdelivering loses trust very quickly,” he explained during a Bloomberg TV interview.
Management outlined ambitious objectives including the development of more than five blockbuster medications by 2030 and generating over $23 billion in incremental sales by 2035. The market response remained skeptical.
Looming Patent Expiration Creates Urgency
The fundamental challenge facing the company revolves around impending patent expirations. Wegovy and Ozempic, which collectively generate approximately three-quarters of Novo’s total revenue, will lose exclusivity protection in both U.S. and European markets during the early 2030s.
This timeline creates significant pressure to develop a robust pipeline capable of offsetting the inevitable revenue erosion. Doustdar confirmed the company is actively evaluating acquisition opportunities to address strategic gaps, with particular emphasis on cardiovascular disease and obesity-adjacent indications.
The cardiovascular focus intensified after the company’s investigational therapy ziltivekimab failed to demonstrate meaningful reduction in heart attack risk during clinical testing earlier this year. Doustdar indicated that external partnerships or acquisitions may be necessary to compensate for this setback.
He acknowledged that compelling acquisition targets within the obesity space remain scarce, suggesting M&A activity will likely concentrate on complementary therapeutic categories.
CagriSema Under Investor Scrutiny
Market attention has centered on CagriSema, the company’s next-generation obesity treatment currently in development. Doustdar expressed confidence that it would rank among the firm’s most successful product introductions in the coming year.
Optimism has been moderated, however, following comparative trial results showing inferior weight reduction versus Eli Lilly’s competing therapy Zepbound. This outcome complicates Novo’s commercial strategy and pricing flexibility.
Regarding capital allocation, the company has maintained steady progress on its share repurchase initiative. During the period from September 14-18, 2026, management acquired 1.09 million B shares. Cumulative repurchases since February have reached 34.17 million B shares valued at DKK 9.63 billion, representing substantial completion of the DKK 15 billion authorization.
Current analyst consensus rates NVO stock as a Hold with a $47.00 price objective. The company maintains a market capitalization of roughly $191.7 billion.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
